CD46 and neoplasm: In a recent investigation, the anti-CD46 (fully human full-length IgG1) antibody YS5, labeled with the radioisotope zirconium-89, demonstrated superior tumor-to-background ratios than [68Ga]Ga-PSMA-11 in murine models [123].